Stuti Dwivedi, Praveencumar R, T Sivakumar, Mahesh Kumar Posa, Ram C Dhakar, Ruchi Tiwari
{"title":"肿瘤遗传学:揭示癌症的基因基础,提高免疫治疗效果。","authors":"Stuti Dwivedi, Praveencumar R, T Sivakumar, Mahesh Kumar Posa, Ram C Dhakar, Ruchi Tiwari","doi":"10.62958/j.cjap.2024.032","DOIUrl":null,"url":null,"abstract":"<p><p>In this review article we will highlight the evidences that how oncogenes are formed due to the physical genetic variations in proto-oncogenes and tumor suppressor genes and various planned immunotherapies which will include- The immune checkpoint inhibitor-opposing antibodies, adoptive cell treatments, and biologic modifiers (cytokines and vaccines). We will make an effort to provide guidance and potential fixes for these issues, along with pertinent sources for foundational research. For suitable studies, a literature search was undertaken from various database sources such as PubMed, EMBASE, and Google Scholar. One type of gene known as an oncogene-a cellular gene that becomes dysfunctional owing to mutation and overexpression-is the cause of cancer. Certain oncogenes seem to inhibit the homeostatic mechanism by limiting the single cell lineage of leukemia stem cells. According to the clonal theory of oncogenes, tumors are thought to begin in a single cell, Moreover, the growth of tumors is closely linked to the prevention of apoptosis, or programmed cell death. These activities of oncogene can be minimized by some immunological therapies.</p>","PeriodicalId":23985,"journal":{"name":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","volume":"40 ","pages":"e20240032"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oncogenetics: Unraveling the Genetic Underpinnings of Cancer for Improved Immunotherapeutic Outcomes.\",\"authors\":\"Stuti Dwivedi, Praveencumar R, T Sivakumar, Mahesh Kumar Posa, Ram C Dhakar, Ruchi Tiwari\",\"doi\":\"10.62958/j.cjap.2024.032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this review article we will highlight the evidences that how oncogenes are formed due to the physical genetic variations in proto-oncogenes and tumor suppressor genes and various planned immunotherapies which will include- The immune checkpoint inhibitor-opposing antibodies, adoptive cell treatments, and biologic modifiers (cytokines and vaccines). We will make an effort to provide guidance and potential fixes for these issues, along with pertinent sources for foundational research. For suitable studies, a literature search was undertaken from various database sources such as PubMed, EMBASE, and Google Scholar. One type of gene known as an oncogene-a cellular gene that becomes dysfunctional owing to mutation and overexpression-is the cause of cancer. Certain oncogenes seem to inhibit the homeostatic mechanism by limiting the single cell lineage of leukemia stem cells. According to the clonal theory of oncogenes, tumors are thought to begin in a single cell, Moreover, the growth of tumors is closely linked to the prevention of apoptosis, or programmed cell death. These activities of oncogene can be minimized by some immunological therapies.</p>\",\"PeriodicalId\":23985,\"journal\":{\"name\":\"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology\",\"volume\":\"40 \",\"pages\":\"e20240032\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62958/j.cjap.2024.032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62958/j.cjap.2024.032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
在这篇综述文章中,我们将重点介绍原癌基因和抑癌基因的物理遗传变异如何形成癌基因的证据,以及各种计划中的免疫疗法,其中包括:免疫检查点抑制剂对抗抗体、收养细胞疗法和生物调节剂(细胞因子和疫苗)。我们将努力为这些问题提供指导和潜在的解决方案,并提供基础研究的相关资料来源。对于合适的研究,我们从 PubMed、EMBASE 和 Google Scholar 等各种数据库来源进行了文献检索。有一种基因被称为癌基因--由于突变和过度表达而功能失调的细胞基因--是导致癌症的原因。某些癌基因似乎通过限制白血病干细胞的单细胞系来抑制平衡机制。此外,肿瘤的生长与细胞凋亡或程序性细胞死亡的阻止密切相关。一些免疫疗法可以最大限度地减少癌基因的这些活动。
Oncogenetics: Unraveling the Genetic Underpinnings of Cancer for Improved Immunotherapeutic Outcomes.
In this review article we will highlight the evidences that how oncogenes are formed due to the physical genetic variations in proto-oncogenes and tumor suppressor genes and various planned immunotherapies which will include- The immune checkpoint inhibitor-opposing antibodies, adoptive cell treatments, and biologic modifiers (cytokines and vaccines). We will make an effort to provide guidance and potential fixes for these issues, along with pertinent sources for foundational research. For suitable studies, a literature search was undertaken from various database sources such as PubMed, EMBASE, and Google Scholar. One type of gene known as an oncogene-a cellular gene that becomes dysfunctional owing to mutation and overexpression-is the cause of cancer. Certain oncogenes seem to inhibit the homeostatic mechanism by limiting the single cell lineage of leukemia stem cells. According to the clonal theory of oncogenes, tumors are thought to begin in a single cell, Moreover, the growth of tumors is closely linked to the prevention of apoptosis, or programmed cell death. These activities of oncogene can be minimized by some immunological therapies.